Lina Hope
MADRID — In a landmark development for the treatment of metastatic breast cancer, researchers have unveiled results from the phase III APEX-Breast01 trial, demonstrating that the novel antibody-drug conjugate (ADC) rolditamig deuderuxtecan (TQB2102) significantly outperforms standard chemotherapy in patients with HER2-low, recurrent, or metastatic breast cancer. The findings, presented at the European Society for Medical Oncology (ESMO) congress, suggest a paradigm shift for a patient population that has long faced limited therapeutic options.
The study, which randomized 543 patients, revealed that rolditamig deuderuxtecan extended median progression-free survival (PFS) to 16.4 months, compared to just 5.5 months for those receiving investigator-choice chemotherapy—a three-fold improvement that has sent ripples of optimism through the oncology community.
The Core Data: A New Benchmark in PFS
The primary endpoint of the APEX-Breast01 trial was progression-free survival in patients with hormone receptor (HR)-positive/HER2-low metastatic breast cancer. The results were stark: the trial observed a 71% reduction in the hazard ratio for disease progression in favor of the novel ADC.
Beyond the primary endpoint, the data demonstrated that the 6-month PFS rate reached an impressive 81.4% in the rolditamig deuderuxtecan cohort, compared to 45.9% in the chemotherapy control group. These figures were confirmed by both independent central review and investigator assessment, lending robustness to the trial’s conclusions.
Furthermore, the secondary endpoint of overall survival (OS) showed a clear trend toward benefit. Preliminary data indicated a 53% reduction in the hazard ratio for death in the HR-positive subgroup, with similar trends observed in the smaller cohort of HR-negative patients. While follow-up continues to confirm the full OS benefit, the early mortality data are highly encouraging.
Chronology of Development: From Concept to Phase III
The journey of rolditamig deuderuxtecan (TQB2102) reflects the rapidly evolving landscape of precision medicine.
- Early Development: Initial preclinical studies identified the agent as a "biparatopic" ADC. Unlike traditional ADCs that target a single epitope on the HER2 receptor, TQB2102 binds to two non-overlapping epitopes. This design is engineered to enhance receptor crosslinking and internalization, making it particularly effective in "HER2-low" tumors, where traditional HER2-targeted therapies often fail to gain traction.
- Phase I Success: Early-phase clinical trials reported an objective response rate (ORR) of 58%, signaling that the drug was not only safe but highly potent in heavily pre-treated patients.
- Breakthrough Designation: In 2025, the U.S. Food and Drug Administration (FDA) granted breakthrough therapy designation to TQB2102 for its potential in HER2-positive colorectal cancer, signaling the agency’s recognition of its unique pharmacological profile.
- The APEX-Breast01 Trial: Conducted across centers in China, this phase III study focused specifically on patients with metastatic HER2-low breast cancer who had not previously received chemotherapy in the metastatic setting. With a median of two prior lines of systemic therapy, the study population represented a "real-world" scenario of advanced, resistant disease.
Comparative Analysis: What Makes TQB2102 Different?
During the ESMO congress, Dr. Shusen Wang of Sun Yat-sen University Cancer Center explained the structural advantage of the drug. "Rolditamig deuderuxtecan’s biparatopic targeting enhances the delivery of the cytotoxic payload," Dr. Wang noted. By maximizing the internalizing capacity of the tumor cell, the drug ensures that more of the toxic payload reaches the intracellular environment, thereby inducing apoptosis more efficiently than standard treatments.
However, the field is becoming increasingly crowded. Other ADCs, such as trastuzumab deruxtecan (T-DXd, Enhertu), have already established a significant footprint. The question for clinicians is no longer just "Does it work?" but "How does it compare?"
Dr. Barbara Pistilli, an invited discussant from the Gustave Roussy Cancer Center in France, provided a nuanced perspective. While she praised the results as "substantial and impressive," she emphasized that the lack of head-to-head trials between different ADCs makes clinical decision-making difficult. "We have multiple agents with similar targets and payloads entering the market," Dr. Pistilli stated. "Without direct comparisons, it is hard to define the exact position of TQB2102 in the treatment algorithm."
Implications for Clinical Practice and Future Research
The success of the APEX-Breast01 trial carries significant implications for the future of breast cancer management.
The Biomarker Challenge
One of the most critical takeaways from the discussion at ESMO was the urgent need for "biologically informed" patient selection. As Dr. Pistilli noted, "If we want to establish whether pharmacological innovation translates into clinical benefit, we need to identify biomarkers that guide optimal patient-ADC matching." Future trials will likely need to incorporate multidimensional biomarkers—beyond simple IHC scoring—to predict which patients will respond best to which specific ADC.
Sequencing Strategies
With an increasing number of ADCs available, the sequencing of these therapies is the next great hurdle. "We need late-phase trials where multidimensional biomarkers are used not only to pick the right ADC for the patient but to determine the optimal sequencing strategy," Dr. Pistilli argued. The medical community must now determine if one ADC should be used first, and if others remain effective after an initial ADC failure.
Safety and Tolerability
Regarding safety, the APEX-Breast01 trial reported that while Grade 3 or higher treatment-related adverse events (TRAEs) were more frequent in the rolditamig deuderuxtecan arm (69.1% vs 42.4%), the discontinuation rate due to these events remained remarkably low at 1.5% in both groups. The most common toxicities were hematologic, which are generally manageable with standard supportive care. Importantly, the incidence of interstitial lung disease (ILD)—a known concern with certain ADCs—remained low, suggesting a favorable safety profile for the agent.
Conclusion: A New Horizon
The APEX-Breast01 trial results offer a compelling case for the inclusion of rolditamig deuderuxtecan as a first-in-class, biparatopic ADC in the treatment landscape for HER2-low breast cancer. By demonstrating a statistically significant and clinically meaningful improvement in PFS, the study provides a robust foundation for future regulatory submissions.
As the drug moves toward potential global approval, the focus of the medical community will shift toward integrating it into standard care. While the "crowded" nature of the ADC market presents a challenge for oncologists in selecting the "best" drug for an individual patient, the progress represented by TQB2102 is undeniable. For patients with metastatic disease, the promise of an additional 10+ months of progression-free life is not just a statistical victory—it is a profound improvement in the quality and duration of survival.
Moving forward, the success of TQB2102 reinforces the importance of continuous innovation in biparatopic targeting and underscores that even within the "HER2-low" classification, there is significant potential for high-impact therapeutic breakthroughs that can change the trajectory of metastatic breast cancer.
Nila Kartika Wati
Neng Nana
